| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
10,640,000 |
| Market
Cap: |
49.26(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.01 - $5 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile LENSAR is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Co.'s existing LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining better visual outcomes, efficiency and reproducibility. Co. is also designing, developing, and seeking regulatory clearance of a system, its ALLY Adaptive Cataract Treatment System, which combines an improved femtosecond laser with a phacoemulsification system in a single, integrated cataract treatment system.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
4,505 |
67,257 |
| Total Buy Value |
$0 |
$0 |
$12,163 |
$201,677 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
6 |
18 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wong Kendra |
Principal Accounting OfficerOf |
• – – |
2022-01-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,336 |
|
20% |
|
| Staab Thomas R Ii |
Chief Financial Officer |
• – – |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
131,409 |
|
- |
|
| Curtis Nicholas T |
Chief Executive Officer |
• • – |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
770,850 |
|
- |
|
| Connaughton Alan B. |
Chief Operating Officer |
• – – |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
266,221 |
|
- |
|
| Link William J Phd |
Director |
– • – |
2020-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
80,157 |
507,694 |
|
- |
|
| Lindstrom Richard L Md |
Director |
– • – |
2020-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
32,127 |
203,463 |
|
- |
|
| Winer Gary M |
Director |
– • – |
2020-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
4,026 |
25,267 |
|
- |
|
| Curtis Nicholas T |
Chief Executive Officer |
• • – |
2020-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
116,622 |
731,585 |
|
- |
|
| Staab Thomas R Ii |
Chief Financial Officer |
• – – |
2020-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
19,276 |
115,657 |
|
- |
|
| Connaughton Alan B. |
Chief Operating Officer |
• – – |
2020-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
39,195 |
251,221 |
|
- |
|
| Winer Gary M |
Director |
– • – |
2020-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
51 |
21,241 |
|
- |
|
| Pdl Biopharma, Inc. |
10% Owner |
– – • |
2020-10-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(8,667,397) |
0 |
|
- |
|
| Pdl Biopharma, Inc. |
10% Owner |
– – • |
2020-09-29 |
4 |
B |
$11.16 |
$97,125 |
D/D |
8,703 |
8,667,397 |
2.45 |
- |
|
| Link William J Phd |
Director |
– • – |
2020-09-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
427,537 |
|
- |
|
| Lindstrom Richard L Md |
Director |
– • – |
2020-09-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
171,336 |
|
- |
|
| Staab Thomas R Ii |
Chief Financial OfficerOfficer |
• – – |
2020-09-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
96,381 |
|
- |
|
| Winer Gary M |
Director |
– • – |
2020-09-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,190 |
|
- |
|
| Curtis Nicholas T |
Chief Executive OfficerOfficer |
• • – |
2020-09-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
614,963 |
|
- |
|
| Pdl Biopharma, Inc. |
10% Owner |
– – • |
2020-09-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,658,694 |
|
- |
|
| Connaughton Alan B. |
Chief Operating OfficerOfficer |
• – – |
2020-09-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
212,026 |
|
- |
|
70 Records found
|
|
Page 3 of 3 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.20 (4.14%) 
